Antioxidant supplementation has a positive effect on oxidative stress and hematological toxicity during oncology treatment in cervical cancer patients
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background and aim
Hematological toxicity and oxidative stress are common in cancer patients. Antioxidant supplementation has been shown to decrease oxidative stress, but there is still controversy on this topic. The aim of this study was to determine the effect of antioxidant supplementation on oxidative stress, hematological toxicity, and quality of life (QoL) in cervical cancer patients.
Randomized, single-blinded controlled trial in women with cervical cancer treated with radiotherapy and chemotherapy with cisplatin. Subjects were randomly assigned to receive antioxidant supplement or placebo supplement. Plasma concentrations of malondialdehyde, free carbonyls, and blood biometry were measured. EORTC quality of life questionnaire was applied before and after oncology treatment. Student’s t test for independent samples and X 2 for categorical variables were performed.
One hundred three patients were randomly assigned to receive treatment with antioxidants 49 (48 %) or placebo 54 (52.40 %). At the end of the oncology treatment, hemoglobin levels were maintained, and global QoL was better only in the supplemented group (p < 0.025).
Antioxidant supplementation in patients treated with chemotherapy and radiotherapy apparently decreased oxidative stress, maintained hemoglobin levels, and improved QoL; however, more studies are needed to study the long-term effect of this intervention.
- Antioxidant supplementation has a positive effect on oxidative stress and hematological toxicity during oncology treatment in cervical cancer patients
Supportive Care in Cancer
Volume 21, Issue 5 , pp 1359-1363
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Cervical cancer
- Oxidative stress
- Antioxidant therapy
- Hematological toxicity and quality of life (QoL)
- Industry Sectors
- Author Affiliations
- 1. Servicio de Oncología, Hospital General de México, pabellón 111, Doctor Balmis No.148, Col. Doctores. Del. Cuauhtémoc, 06726, Mexico D. F., Mexico
- 2. Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico
- 3. Universidad Iberoamericana, México D. F., Mexico
- 4. Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico